The Difference Between GLP-1, GIP, and Glucagon Receptor Targets
A side-by-side look at the difference between GLP-1, GIP, and glucagon receptor targets, covering where each sits, what it responds to, and how listings use the distinction.
Reviewed by Sarah Chen, MD, endocrinologist ·
Sarah Chen, MD is a board-certified endocrinologist with 14 years of clinical and research experience in metabolic disorders and hormonal therapeutics, with fellowship training at Johns Hopkins Hospital.
The difference between GLP-1, GIP, and glucagon receptor targets comes down to three separate receptor proteins, each with its own natural ligand, its own tissue distribution, and its own signaling behavior once activated. A compound’s classification as a single, dual, or triple agonist is really just a shorthand for which of these three receptors its sequence is built to bind. Understanding what separates the three targets makes that shorthand legible instead of just a label to memorize.
What “Receptor Target” Means on a Spec Sheet
A receptor target is the specific receptor protein a peptide is designed to bind and activate. Receptors are not interchangeable locks that any similarly shaped key can open — each one has a binding site shaped for its own natural ligand, and a peptide only activates the receptors its sequence is complementary to. When a spec sheet lists “receptor targets: GLP-1, GIP, glucagon,” it is stating a structural fact about the peptide’s binding profile, not a claim about strength or effect.
This is why receptor count and receptor identity both matter when reading a listing. Two compounds can each target two receptors and still not be equivalent, because which two receptors are involved changes the pathways being engaged.
The GLP-1 Receptor
GLP-1 stands for glucagon-like peptide-1, and its receptor is the target shared by every compound in the single, dual, and triple agonist families discussed on this site. The GLP-1 receptor is distributed across the pancreas, the gut, and regions of the central nervous system, and it is the most extensively referenced target in this compound class, largely because it was the first of the three to be isolated and studied at scale.
Compounds described as “GLP-1 receptor agonists” bind only this one target. That single-target profile is what separates them, structurally, from the dual- and triple-target compounds that also carry the GLP-1 label as one part of a broader binding profile.
The GIP Receptor
GIP stands for glucose-dependent insulinotropic polypeptide, and its receptor is structurally distinct from the GLP-1 receptor even though the two are frequently discussed together. GIP receptors are expressed in the pancreas, adipose tissue, and parts of the central nervous system, with a distribution that overlaps the GLP-1 receptor’s in some tissues and diverges from it in others.
A compound that adds GIP receptor activity to a GLP-1 receptor profile is classified as a dual agonist. Tirzepatide is the most commonly referenced example in listings that use this two-target classification, and its naming exists specifically to signal that it engages both receptors rather than one.
The Glucagon Receptor
The glucagon receptor is the third target in this family, and it is the one that distinguishes triple agonists from dual agonists. Its natural ligand, glucagon, is a distinct peptide hormone from both GLP-1 and GIP, and the glucagon receptor’s downstream signaling pathway is correspondingly separate from the other two, even though all three receptors belong to the same broader receptor family.
Retatrutide’s classification as a triple agonist reflects the addition of this third target on top of the GLP-1 and GIP receptor activity already present in dual-agonist compounds. Retatrutide is described in listings as targeting all three because its sequence is built to activate the glucagon receptor in addition to the other two, not because it acts on any single receptor more intensely.
Comparing the Three Targets
The table below lines up the three receptors by natural ligand and by where each shows up in the single, dual, and triple agonist classification scheme most often used in listings.
| Receptor | Natural ligand | Added in which compound class |
|---|---|---|
| GLP-1 receptor | GLP-1 | Present in single, dual, and triple agonists |
| GIP receptor | GIP | Added in dual and triple agonists |
| Glucagon receptor | Glucagon | Added only in triple agonists |
Reading the table this way shows that the classification scheme is cumulative rather than a ranking. Each step up in target count adds one specific receptor, not a general increase in potency, and the receptor being added is always named explicitly in the classification.
Why Receptor Count Shows Up in Compound Naming
Naming conventions in this space are built around receptor count because it is the fastest way to communicate a structural fact without printing the full sequence. “Single,” “dual,” and “triple” tell a reader how many of the three receptors discussed above a given compound is designed to bind, before they look at the molecular formula or amino acid sequence.
This naming convention is also why the receptor targets matter more than a raw target count when comparing two compounds. A hypothetical dual agonist that targeted GLP-1 and glucagon receptors, skipping GIP, would not be equivalent to tirzepatide’s GLP-1/GIP profile, even though both would technically qualify as “dual agonists.” The identity of the targets, not just the count, is what a full spec sheet needs to convey. Listings that source their compounds from a broader catalogue, such as the retatrutide entry at heezresearch.com/product/retatrutide/, typically spell out all three targets by name for exactly this reason, rather than relying on the classification word alone.
Reading Receptor-Target Claims on a Listing
When a listing states receptor targets directly, it is giving the same information the single/dual/triple classification implies, just spelled out. Cross-checking the two against each other is a useful way to catch inconsistent labeling, since a listing that says “triple agonist” but names only two receptors is internally inconsistent and worth flagging before treating the rest of the spec sheet as reliable.
Other resources tracking this same terminology across the reta compound family present the receptor-target breakdown in slightly different formats. The index at retainfo.com is one example of a site organizing this information by compound, while retaonline.net structures a comparable reference around the same three-receptor framework. Comparing formats across sources is a reasonable way to confirm that a given listing’s classification and its named targets actually line up.
Summary
The difference between GLP-1, GIP, and glucagon receptor targets is a difference in three distinct receptor proteins, each with its own natural ligand and its own place in the single, dual, and triple agonist naming scheme. GLP-1 receptor activity appears across all three classes, GIP receptor activity marks the step up to a dual agonist, and glucagon receptor activity marks the step up to a triple agonist. Reading a listing’s named targets alongside its classification word is the most reliable way to confirm what a compound is actually built to do at the receptor level.
A note on how to read this
This article is written for research and educational reference. The materials described are sold for laboratory research and are not for human consumption. Nothing here is dosing guidance, a prescription, or a clinical recommendation.